A team of investigators sought to evaluate outcomes following combination treatment with eprenetapopt and azacitadine in TP53-mutant myelodysplastic syndromes, as well as in oligoblastic acute myeloid leukemia.
Study results suggest that the cost-effectiveness of daratumumab use may be lower with first- vs second-line therapy of transplant-ineligible multiple myeloma.
Lenalidomide is typically prescribed to individuals with multiple myeloma who have received at least 1 prior therapy.
Study finds correlation between certain laboratory markers and symptom burden in patients with relapsed/refractory multiple myeloma.
Investigators reported the results of the phase 3 MAIA trial on HRQOL outcomes in patients with transplant-ineligible, newly diagnosed MM.
Several biomarkers were predictive of progression from smoldering MM to MM, according to a retrospective study.
The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.
This retrospective analysis explored the impact of beta blocker therapy on survival in patients with relapsed or refractory multiple myeloma receiving pomalidomide.
Combined with dexamethasone, melflufen may be efficacious among patients with heavily pretreated relapsed and refractory multiple myeloma.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
